Qiqi He1,2, Melissa A Babcook1, Sanjeev Shukla1, Eswar Shankar1, Zhiping Wang2, Guiming Liu3, Bernadette O Erokwu4, Chris A Flask4,5,6, Lan Lu1,4, Firouz Daneshgari3, Gregory T MacLennan7, Sanjay Gupta1. 1. Department of Urology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio. 2. Department of Urology, Key Laboratory of Disease of Urological Systems, Gansu Nephro-Urological Clinical Center, Second Hospital of Lanzhou University, Lanzhou, Gansu, China. 3. Department of Surgery, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio. 4. Department of Radiology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio. 5. Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio. 6. Department of Pediatrics, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio. 7. Department of Pathology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio.
Abstract
OBJECTIVE: Accumulating evidences suggests that obesity and metabolic syndrome (MetS) contribute towards lower urinary tract symptoms (LUTS) through alterations in the phenotype of bladder and prostate gland. Clinical studies indicate a link between MetS and LUTS. Nevertheless, there is lack of suitable animal model(s) which could illustrate an association linking obesity to LUTS. We examined the lower urinary tract function in an obesity-initiated MetS mouse model. METHODS: Male C57BL/6N wild-type and obese B6.V-Lepob/J maintained on regular diet for 28 weeks were subjected to the assessment of body weight (BW), body length (BL), waist circumference (WC), body mass index (BMI), blood glucose (BG), plasma insulin (INS), plasma leptin (LEP), total cholesterol (CHO), free fatty acid (FFA), and measurement of urinary functions. Whole animal peritoneal and subcutaneous adipose tissue measurements as well as prostate and bladder volumes were analyzed by MRI followed by histological evaluation. These parameters were used to draw correlations between MetS and LUTS. RESULTS: Obesity parameters such as BW, WC, and BMI were significantly higher in B6.V-Lepob/J mice compared to C57BL/6N mice (P < 0.01). Higher levels of total CHO and FFA were noted in B6.V-Lepob/J mice than C57BL/6N mice (P < 0.05). These results were concurrent with frequency, lower average urine volume and other urinary voiding dysfunctions in B6.V-Lepob/J mice. MRI assessments demonstrate marked increase in body fat and prostate volume in these mice. Compared to C57BL/6N mice, histological analysis of the prostate from B6.V-Lepob/J mice showed increased proliferation, gland crowding, and infiltration of immune cells in the stroma; whereas the bladder urothelium was slightly thicker and appears more proliferative in these mice. The regression and correlation analysis indicate that peritoneal fat (R = 0.853; P < 0.02), CHO (R = 0.729; P < 0.001), BG (R = 0.712; P < 0.001) and prostate volume (R = 0.706; P < 0.023) strongly correlate with LUTS whereas BMI, WC, INS, and FFA moderately correlate with the prevalence of bladder dysfunction. CONCLUSION: Our results suggest that LUTS may be attributable in part to obesity and MetS. Validation of an in vivo model may lead to understand the underlying pathophysiological mechanisms of obesity-related LUTS in humans. Prostate 76:964-976, 2016.
OBJECTIVE: Accumulating evidences suggests that obesity and metabolic syndrome (MetS) contribute towards lower urinary tract symptoms (LUTS) through alterations in the phenotype of bladder and prostate gland. Clinical studies indicate a link between MetS and LUTS. Nevertheless, there is lack of suitable animal model(s) which could illustrate an association linking obesity to LUTS. We examined the lower urinary tract function in an obesity-initiated MetS mouse model. METHODS: Male C57BL/6N wild-type and obese B6.V-Lepob/J maintained on regular diet for 28 weeks were subjected to the assessment of body weight (BW), body length (BL), waist circumference (WC), body mass index (BMI), blood glucose (BG), plasma insulin (INS), plasma leptin (LEP), total cholesterol (CHO), free fatty acid (FFA), and measurement of urinary functions. Whole animal peritoneal and subcutaneous adipose tissue measurements as well as prostate and bladder volumes were analyzed by MRI followed by histological evaluation. These parameters were used to draw correlations between MetS and LUTS. RESULTS:Obesity parameters such as BW, WC, and BMI were significantly higher in B6.V-Lepob/J mice compared to C57BL/6N mice (P < 0.01). Higher levels of total CHO and FFA were noted in B6.V-Lepob/J mice than C57BL/6N mice (P < 0.05). These results were concurrent with frequency, lower average urine volume and other urinary voiding dysfunctions in B6.V-Lepob/J mice. MRI assessments demonstrate marked increase in body fat and prostate volume in these mice. Compared to C57BL/6N mice, histological analysis of the prostate from B6.V-Lepob/J mice showed increased proliferation, gland crowding, and infiltration of immune cells in the stroma; whereas the bladder urothelium was slightly thicker and appears more proliferative in these mice. The regression and correlation analysis indicate that peritoneal fat (R = 0.853; P < 0.02), CHO (R = 0.729; P < 0.001), BG (R = 0.712; P < 0.001) and prostate volume (R = 0.706; P < 0.023) strongly correlate with LUTS whereas BMI, WC, INS, and FFA moderately correlate with the prevalence of bladder dysfunction. CONCLUSION: Our results suggest that LUTS may be attributable in part to obesity and MetS. Validation of an in vivo model may lead to understand the underlying pathophysiological mechanisms of obesity-related LUTS in humans. Prostate 76:964-976, 2016.
Authors: Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi Journal: Eur Urol Date: 2012-02-25 Impact factor: 20.096
Authors: Michael G Kirby; Adrian Wagg; Linda Cardozo; Christopher Chapple; David Castro-Diaz; Dirk de Ridder; Montserrat Espuna-Pons; Francois Haab; Con Kelleher; Heinz Kölbl; Ian Milsom; Philip Van Kerrebroeck; Mark Vierhout; Stefano Salvatore; Andrea Tubaro Journal: Neurourol Urodyn Date: 2010-11 Impact factor: 2.696
Authors: Francesco Cantiello; Antonio Cicione; Andrea Salonia; Riccardo Autorino; Giuseppe Ucciero; Luigi Tucci; Alberto Briganti; Rocco Damiano Journal: Int J Urol Date: 2013-08-04 Impact factor: 3.369
Authors: Mehrnaz Gharaee-Kermani; Jose A Rodriguez-Nieves; Rohit Mehra; Chad A Vezina; Aruna V Sarma; Jill A Macoska Journal: Prostate Date: 2013-03-26 Impact factor: 4.104
Authors: Sherita H Golden; Karen A Robinson; Ian Saldanha; Blair Anton; Paul W Ladenson Journal: J Clin Endocrinol Metab Date: 2009-06 Impact factor: 5.958
Authors: Shelby A Powers; Terence E Ryan; Elena S Pak; Matthew O Fraser; Joseph M McClung; Johanna L Hannan Journal: Neurourol Urodyn Date: 2019-05-10 Impact factor: 2.696
Authors: Scott R Bauer; Stephanie L Harrison; Peggy M Cawthon; Angela Senders; Stacey A Kenfield; Anne M Suskind; Charles E McCulloch; Kenneth Covinsky; Lynn M Marshall Journal: J Gerontol A Biol Sci Med Sci Date: 2022-10-06 Impact factor: 6.591
Authors: Mariana G de Oliveira; Matheus L de Medeiros; Edith B G Tavares; Fabiola Z Mónica; Edson Antunes Journal: Front Physiol Date: 2020-04-03 Impact factor: 4.566